Research Library
Curated Studies & Clinical Data
A growing library of peer-reviewed studies, clinical trial data, and systematic reviews organized by compound. Every citation is linked to its primary source.
Gastric content and aspiration risk after semaglutide cessation: a reply
Anaesthesia, 2026
Evaluation of tirzepatide as an adjunct to buprenorphine for the treatment of opioid use disorder (TAB) trial: study design and rationale
Contemporary clinical trials, 2026;:108437
Clinical efficacy of switching to tirzepatide in patients with type 2 diabetes and a high risk of metabolic dysfunction-associated steatotic liver disease undergoing GLP-1 receptor agonist therapy: Insights from the Hokkaido-TZP study
Journal of diabetes and its complications, 2026;:109391
GLP-1 and GLP-1/GIP receptor agonist medication use and self-reported outcomes in individuals with lipedema: Results from a large online survey
Obesity pillars, 2026;19:100316
Beyond Weight Loss: Skeletal Muscle Health During Incretin-Based Therapy in Patients with Diabesity
Nutrients, 2026;18(16)
GLP-1 and GIP class drugs have neuroprotective properties in Alzheimer’s and Parkinson’s disease
Frontiers in neuroscience, 2026;20:1906426
Medical nutrition therapy in incretin-treated obesity-related heart failure with preserved ejection fraction
Frontiers in nutrition, 2026;13:1914155
Clinical efficacy of tirzepatide for weight regain and suboptimal glycemic control following laparoscopic sleeve gastrectomy: a case series of three patients with obesity-associated type 2 diabetes
Frontiers in endocrinology, 2026;17:1895420
Once-weekly IcoSema versus once-daily insulin glargine U100 in type 2 diabetes management (COMBINE 4): an open-label, multicentre, treat-to-target, randomised, phase 3b trial
The lancet. Diabetes & endocrinology, 2026
Achieving the triple endpoint of body weight reduction thresholds, systolic blood pressure reduction ≥5 mmHg and non-HDL cholesterol <130 mg/dL with tirzepatide in people with obesity: A post hoc analysis from the SURMOUNT trials
PloS one, 2026;21(8):e0345032
Gastroparesis induced by glucagon-like peptide-1 receptor agonists: A systematic review of clinical features, diagnosis, management, and outcomes
PloS one, 2026;21(8):e0354497
Validation of a Pharmacist-Led Semaglutide Prescribing Algorithm for Type 2 Diabetes and Chronic Kidney Disease: Research Letter
Canadian journal of kidney health and disease, 2026;13:20543581261476643
Serum GDF3 is Associated with Visceral Obesity, Insulin Resistance, and Inflammation in Non-Diabetic Adults: A Cross-Sectional Study with an Interventional Component
Diabetes, metabolic syndrome and obesity : targets and therapy, 2026;19:609998
Comparative Efficacy of Semaglutide and Tirzepatide in Chinese Adults with Obesity without Diabetes: A Real-World Observational Study
Diabetes, metabolic syndrome and obesity : targets and therapy, 2026;19:607678
Comparative effects of semaglutide tirzepatide and retatrutide on renal fibrosis in UUO and aged mice
iScience, 2026;29(9):117174
Do Patients Receiving GLP-1 Receptor Agonists for Weight Loss Require Structured Dietetic Care? Lessons from Metabolic and Bariatric Surgery (MBS) Pathways
Nutrients, 2026;18(16)
The liver-gut-brain axis in metabolic dysfunction-associated steatotic liver disease: bidirectional communication, clinical implications, and future perspectives
Frontiers in endocrinology, 2026;17:1911290
The menopause-obesity axis in MASH progression: from estrogen decline to liver fibrosis
Frontiers in gastroenterology (Lausanne, Switzerland), 2026;5:1889458
Comparative Efficacy and Safety of Tirzepatide Versus Semaglutide for Obesity: A Systematic Review
Cureus, 2026;18(8):e114454
Dapagliflozin Alone or Combined With Semaglutide: Cardiovascular and Renal Outcomes Among Patients With Type 2 Diabetes Mellitus in a 6-Month Real-World Retrospective Cohort Study in Saudi Arabia
Journal of the ASEAN Federation of Endocrine Societies, 2026;41(2):75-84